XTLB Relative Valuation
XTLB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, XTLB is overvalued; if below, it's undervalued.
Historical Valuation
X T L Biopharmaceuticals Ltd (XTLB) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.03 is considered Undervalued compared with the five-year average of 10.21. The fair price of X T L Biopharmaceuticals Ltd (XTLB) is between 214.44 to 218.52 according to relative valuation methord. Compared to the current price of 1.22 USD , X T L Biopharmaceuticals Ltd is Undervalued By 99.43%.
Relative Value
Fair Zone
214.44-218.52
Current Price：1.22
99.43%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
214.08
P/B
Median3y
275.67
Median5y
316.47
-15.44
FCF Yield
Median3y
-3.75
Median5y
-3.16
Competitors Valuation Multiple
The average P/S ratio for XTLB's competitors is 25.13, providing a benchmark for relative valuation. X T L Biopharmaceuticals Ltd Corp (XTLB) exhibits a P/S ratio of 0.03, which is -99.87% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is X T L Biopharmaceuticals Ltd (XTLB) currently overvalued or undervalued?
What is X T L Biopharmaceuticals Ltd (XTLB) fair value?
How does XTLB's valuation metrics compare to the industry average?
What is the current P/B ratio for X T L Biopharmaceuticals Ltd (XTLB) as of Jul 08 2025?
What is the current FCF Yield for X T L Biopharmaceuticals Ltd (XTLB) as of Jul 08 2025?
What is the current Forward P/E ratio for X T L Biopharmaceuticals Ltd (XTLB) as of Jul 08 2025?